Title : Novel therapeutic strategies to improve t-PA therapy and promote recovery after stroke
Each year 15 million people suffer from a stroke and it is the number one cause of disability worldwide and a major drain on health cost. The only available FDA-approved drug therapy for ischemic stroke today is tissue plasminogen activator (t-PA), which is used to dissolve the occluding clot. However, less than 10% of patients actually receive this therapy because of the very limited time-window in which t-PA can be safely administered. If t-PA is given later than 4.5 hours after stroke onset, the patient is at risk for a hemorrhagic transformation within the infarct. It is thought that metalloproteinases (MMPs) are the key culprit in causing hemorrhagic transformation. In this presentation a therapeutic approach which improve the safety of t-PA administration by blocking MMP-9 will be presented. Our results suggest that blocking MMP-9 is a promising adjuvant strategy to alleviate the detrimental side effects of delayed t-PA treatment. These results provide new insights into how we can improve the only FDA approved treatment for ischemic stroke.
Audience take away:
- Insight into how we can improve the only FDA approved drug